title: [Nondetectable prostate cancer in radical prostatectomy specimens].
abstract: Since the widespread use of prostate-specific antigen, early diagnosis of prostate cancer at an early stage has been increased. Consequently, a greater frequency of low-volume disease or no tumor has been found in radical prostatectomy specimen.
  
  
  OBJECTIVE
  In the present study authors analyzed patients classified as pT0 after radical prostatectomy at their center.
  
  
  METHODS
  1134 radical prostatectomies were evaluated retrospectively at the author's center between 1996 and 2010. If there was no evidence of prostate cancer in the specimen, patient was staged as pT0. Patients were divided into two groups: received neoadjuvant hormonal therapy or not.
  
  
  RESULTS
  Overall 32 (2.8%) patients were staged as pT0. The rate of pT0 staging was 9.3% and 1.2% in the hormonally treated group and non-hormonally treated group. False-positive prostate biopsy was found in 2 cases. The rate of pT0 staging was higher in patients with incidental prostate cancer, low Gleason score and enlarged prostate. Biochemical relapse was observed in 3 pT0 patients in the hormonally treated group, among them there was one clinical relapse. In non-hormonally treated group no recurrence was detected.
  
  
  CONCLUSIONS
  The rate of pT0 staging was higher in the hormonally treated group. Because of biochemical and clinical relapse despite vanishing prostate cancer phenomenon, these cases are considered not to be true pT0. On the basis of present study and other reports the rate of pT0 staging is about one percentage in non-hormonally treated patients. Prognosis of these patients is excellent.
authors.affiliation: Orvos- és Egészségtudományi Centrum Urológiai Klinika Debrecen Nagyerdei krt. vezermurmillo@gmail.com
authors.forename: Mihály
authors.initials: M
authors.lastname: Murányi
authors.forename: Ali Salah
authors.initials: AS
authors.lastname: Morshed
authors.forename: Mátyás
authors.initials: M
authors.lastname: Benyó
authors.forename: Csaba
authors.initials: C
authors.lastname: Tóth
authors.forename: Tibor
authors.initials: T
authors.lastname: Flaskó
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D006814:Hungary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000379:methods / Q000706:statistics & numerical data; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000601:surgery; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen